1. Home
  2. CAPR vs UAMY Comparison

CAPR vs UAMY Comparison

Compare CAPR & UAMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$35.29

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

HOLD

Current Price

$10.27

Market Cap

1.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
UAMY
Founded
2005
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2011
1997

Fundamental Metrics

Financial Performance
Metric
CAPR
UAMY
Price
$35.29
$10.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$44.63
$9.44
AVG Volume (30 Days)
1.0M
9.9M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,257,708.00
Revenue This Year
N/A
$219.89
Revenue Next Year
$3.31
$104.28
P/E Ratio
N/A
N/A
Revenue Growth
N/A
162.80
52 Week Low
$4.30
$1.94
52 Week High
$40.37
$19.71

Technical Indicators

Market Signals
Indicator
CAPR
UAMY
Relative Strength Index (RSI) 65.11 55.44
Support Level $22.09 $6.57
Resistance Level $36.49 $11.01
Average True Range (ATR) 2.10 0.85
MACD 0.21 0.19
Stochastic Oscillator 79.14 62.91

Price Performance

Historical Comparison
CAPR
UAMY

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

Share on Social Networks: